Shire Australia

20 PBAC submissions on file, active 2008–2020. 55% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Icatibant
  Rare disease · Recommended with restriction · 2017—
• Lisdexamfetamine
  Neurology · Recommended with restriction · 2020—
• Teduglutide
  Gastroenterology · Recommended with restriction · 2021other sponsor
• Guanfacine
  Neurology · Recommended with restriction · 2018—
• Lanadelumab
  Immunology · Recommended with restriction · 2024other sponsor
• Velaglucerase alfa
  Rare disease · Noted · 2012—
• Irinotecan (nanoliposomal)
  Oncology · Not recommended · 2024other sponsor
• Lanthanum carbonate hydrate
  Endocrinology · Deferred · 2008—
• Lisdexamfetamine dimesilate
  Mental health · Recommended with restriction · 2014—
• Mesalazine
  Gastroenterology · Recommended · 2020other sponsor

Therapy area mix

Activity by year

2008 (1) · 2010 (1) · 2011 (2) · 2012 (1) · 2013 (1) · 2014 (1) · 2015 (1) · 2016 (1) · 2017 (3) · 2018 (3) · 2019 (3) · 2020 (2)

Rejection patterns

Across 7 Not recommended decisions on file.

• 1×Uncertain long-term benefit
• 1×inappropriate restriction criteria (12-month parenteral support dependency may not identify appropriate population)
• 1×continuing treatment response criterion (20% volume reduction) not clinically substantiated
• 1×proposed extended initial treatment criterion not appropriate
• 1×lack of stopping rule